BAHEAL Pharmaceutical Holdings Limited Controls Shares of Tarcine BioMedPublished: 2014-12-19 10:25
On June 16, 2011, Pearl Ocean officially signed with Tarcine BioMed (Beijing) Inc. and controlled its shares. Tarcine BioMed is a high-tech enterprise founded in 2005 by overseas returnees, engaged in the clinical application of the advanced scientific research achievements in cell biology, molecular biology, immunology and other fields, as well as the research and development of the early atraumatic diagnostic techniques and treatment techniques of serious human diseases by technologies with independent intellectual property rights. Currently, the company’s product research, development and production are mainly involved in early diagnosis of cancer, organ injury /organ transplantation, blood concentration monitoring, cardiovascular and cerebrovascular disease diagnosis and other fields. The early diagnostic kit of nasopharyngeal carcinoma (NPC) is the only kit indicated for “NPC auxiliary diagnosis” approved by China's State Food and Drug Administration (SFDA). So far, Tarcine BioMed has owned more than 10 national patents in related fields. Being the holding company of Tarcine BioMed marks that Pearl Ocean has entered the medical high-tech frontier field of diagnostic reagent, and Pearl Ocean will surely make new contributions to China's medical health development.